The effect of processed honey and royal jelly on cancer-related fatigue

Evaluation of the effect of processed honey and royal jelly on cancer-related fatigue: a double blind randomized clinical trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015081423426N1

Enrollment

Registered

2015-09-08

Start date

2012-03-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms. ---

Interventions

Intervention 1: Intervention group 1: 26 patients received processed honey and royal jelly. Processed honey and royal jelly, made under standard-state conditions with the permission of food and drug o

Treatment - Drugs

Placebo

Intervention group 1: 26 patients received processed honey and royal jelly. Processed honey and royal jelly, made under standard-state conditions with the permission of food and drug organization of m

Control group : 26 patients received pure honey . Pure honey , made under standard-state conditions with the permission of food and drug organization of ministry of health and medical education of Ira

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age more than 18; having the diagnosis of a solid (non-hematologic) malignancy; visual analogue scale (VAS) more than 4; Karnofsky Performance Status (KPS) more than 70; serum hemoglobin level of more than 8g/dL with no abrupt decrease (more than 2g/dl) during the last month; Liver enzymes not more than three times above the normal limits; serum total bilirubin less than 2mg/dL; serum creatinine less than 2mg/dL and creatinine clearance more than 60ml/mi. Exclusion criteria: Patients with hypersensitivity to honey, uncontrolled cardiac or respiratory problems; any other serious medical condition, including severe infection or uncontrolled pain; pregnancy, major depression; taking medications with potential effects on fatigue; such as psychiatric medication (anti-depressants; psychostimulants,etc) or growth factors like erythropoietin.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cancer-related fatigue. Timepoint: Before intervention, 2 Weeks after intervention and 4 weeks after intervention. Method of measurement: Fatigue Severity Scale.	—

Secondary

Measure	Time frame
--. Timepoint: --. Method of measurement: --.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahram Mofid

Shahid Beheshti University of Medical Sciences, Tehran, Iran

mofid429@yahoo.com+98 21 2272 8081

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 13, 2026